Q-omics provides the consensus-scored JCADP1 profile across patient tissues and cancer cell-line models. JCADP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, JCADP1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, JCADP1 RNA expression shows 8,067 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight HNSC, COAD, and SARC as cancer lineages where JCADP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JCADP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JCADP1 survival associations across molecular data types. JCADP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JCADP1 RNA expression–survival associations across cancer types. High JCADP1 expression shows unfavorable associations in LUAD, MESO, THCA, UVM and THYM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for JCADP1 RNA expression.
This table summarizes JCADP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for JCADP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JCADP1 shows lower tumor expression in COAD and READ and higher tumor expression in UCEC, BRCA, LUAD and LIHC. The COAD box plot shows higher JCADP1 RNA expression in normal versus tumor tissue (log2 FC = −0.050, t-test p = .001).
This table shows molecular features associated with JCADP1 in patient tissues and cancer cell lines. In patient samples, JCADP1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
